{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-082787","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.133830+00:00","generated_at":"2026-05-15T23:08:41.206572+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aardvark Therapeutics pauses Phase 3 HERO trial for ARD-101 in PWS due to cardiac signals","bullets":["Voluntary pause of Phase 3 HERO trial (NCT06828861) and open-label extension (NCT07197034) for ARD-101 in Prader-Willi Syndrome.","Decision based on reversible cardiac observations at above-target therapeutic doses in a healthy volunteer study.","No longer expects topline data in Q3 2026; plans to provide guidance in Q2 2026.","Company conducting comprehensive data review and collaborating with FDA and clinical experts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-082787","json":"https://secwatch.observer/filing/0001193125-26-082787.json","markdown":"https://secwatch.observer/filing/0001193125-26-082787.md","text":"https://secwatch.observer/filing/0001193125-26-082787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526082787/0001193125-26-082787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000119312526082787/ck0001774857-20260227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:08:41.206572+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}